Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Archivos De La Sociedad Espanola De Oftalmologia|October 1, 2003
[Perimetric changes after surgery in advanced glaucoma]J F Casiraghi, M A Moussalli, P I Lavena
Medicina|February 1, 2015
Prevalence of disc cupping in non-glaucomatous eyesJosé Pablo Chiappe, Pablo Nahum, Javier F Casiraghi, et al.
Archivos De La Sociedad Espanola De Oftalmologia|April 1, 2008
[Comparative study of the effects of two anti-glaucomatous drugs on the corneal thickness in rabbits with corneal autografts]P A Chiaradia, J F Casiraghi, J Fischbarg, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|December 1, 1995
Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritisM Noris, S Bernasconi, F Casiraghi, et al.
Kidney International|February 23, 1999
Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockadeP Ruggenenti, L Mosconi, F Sangalli, et al.
Transplantation|May 27, 1997
Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunctionF Casiraghi, P Ruggenenti, M Noris, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 12, 1997
Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failureP Boccardo, D Melacini, S Rota, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 1, 1992
Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activationM Noris, A Benigni, R Siegler, et al.
Journal of the American Society of Nephrology : JASN|June 30, 1998
Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritisS Tomasoni, M Noris, S Zappella, et al.
Clinical Therapeutics|November 24, 2007
A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%Eugenio Maul, Félix Gil Carrasco, Vital Paulino Costa, et al.
Pageof 2